Related Experiment Video
Updated: Jul 4, 2026
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration
Xiaoyuan Huang1, Liang Zhuang, Yang Cao
1Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Abstract:
Oncolytic adenoviruses represent a promising novel therapeutic option for the treatment of cancer. Despite their demonstrated safety in human clinical trials, the fundamental properties of oncolytic adenovirus biodistribution, spread, viral persistence, and replication in vivo have not been well characterized. The aim of this study was to evaluate the kinetics of viral distribution, spread, replication, and antitumoral efficacy after i.v. administration of a novel oncolytic mutant M1. This mutant consists of the E1A CR2-deleted Adv5 with a fragment of antisense polo-like kinase 1 (plk1) cDNA inserted into the deleted 6.7K/gp19K region, which combines oncolytic properties with efficient plk1 silencing, as described in our previous reports. In the present study, we established a new human orthotopic gastric carcinoma with a high frequency metastasis mouse model and showed that M1 spread not only in local primary tumors but also in disseminated metastases. M1 could effectively replicate in tumor cells leading to "oncolysis" and was able to eliminate expression of the targeted gene plk1 in human orthotopic gastric carcinoma model mice. Therefore, i.v. administration of M1 could prolong the survival time of tumor-bearing mice.
Insights
Novel oncolytic adenovirus M1 effectively targets gastric cancer metastases. Intravenous administration of M1 promotes viral spread, replication, and gene silencing, prolonging survival in preclinical models.
Area of Science:
- Oncolytic virotherapy
- Cancer gene therapy
- Adenovirus research
Background:
- Oncolytic adenoviruses show promise for cancer treatment but require better characterization of in vivo behavior.
- Understanding biodistribution, spread, and replication is crucial for optimizing oncolytic adenovirus therapies.
- The novel M1 mutant combines oncolytic properties with polo-like kinase 1 (plk1) gene silencing.
Purpose of the Study:
- To evaluate the biodistribution, spread, replication kinetics, and antitumoral efficacy of the novel oncolytic adenovirus M1.
- To assess the in vivo performance of M1 after intravenous administration in a human orthotopic gastric carcinoma metastasis model.
Main Methods:
- Development of a human orthotopic gastric carcinoma with high metastasis frequency mouse model.
- Intravenous administration of the M1 oncolytic adenovirus mutant.
- Evaluation of viral distribution, spread, replication, plk1 gene silencing, and survival rates.
Main Results:
- M1 demonstrated spread to both primary tumors and disseminated metastases.
- Effective viral replication within tumor cells led to oncolysis.
- M1 successfully eliminated plk1 gene expression in the gastric carcinoma model.
- Intravenous administration of M1 significantly prolonged survival time in tumor-bearing mice.
Conclusions:
- The M1 oncolytic adenovirus exhibits promising therapeutic potential for gastric cancer, including metastatic disease.
- Intravenous delivery of M1 facilitates systemic tumor targeting and effective oncolysis.
- M1's ability to silence plk1 contributes to its antitumoral efficacy and improved survival outcomes.
